CLINICAL_TRIALS
trial_result
· 2014-04-08
Clinical Trial Update: (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF [Phase 3]
Summary
The ARTEMIS-IPF Phase 3 trial evaluating ambrisentan for idiopathic pulmonary fibrosis was terminated and results were posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2014-04-08